Currency In USD
| Previous Close | 0.81 |
| Open | 0.82 |
| Day High | 0.84 |
| Day Low | 0.78 |
| 52-Week High | 12.23 |
| 52-Week Low | 0.74 |
| Volume | 2.27M |
| Average Volume | 2.59M |
| Market Cap | 12.96M |
| PE | -0.19 |
| EPS | -4.28 |
| Moving Average 50 Days | 0.96 |
| Moving Average 200 Days | 1.73 |
| Change | 0.01 |
Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026
GlobeNewswire Inc.
Mar 11, 2026 12:00 PM GMT
Cincinnati Children’s Applied Gene and Cell Therapy Center selected to conduct tech transfer, development and IND-enabling manufacturingAll activities other than long-term stability testing planned to be complete in Q3 2026 to support potential IND f
Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026
GlobeNewswire Inc.
Feb 25, 2026 12:59 PM GMT
100% complete response (CR) rate among all six efficacy evaluable patientsFavorable safety profile with no Grade >3 CRS or ICANSPrior investigator-initiated trial (IIT) reached median progression free survival (PFS) of 23.1 months, including in patie
Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets
GlobeNewswire Inc.
Feb 11, 2026 11:59 AM GMT
Tempest outlines a capital-efficient post-transaction strategy to advance a diversified portfolio of next-generation CAR-T and oncology assetsDevelopment approach prioritizes partner-funded and externally supported programs to generate clinical data